Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

8.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.3K
T Cell Types and Functions01:24

T Cell Types and Functions

3.3K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.3K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

86.4K
Overview
86.4K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

17.4K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
17.4K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

3.1K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis.

Cell death & disease·2021
Same author

Addressing challenges to rolling out COVID-19 vaccines in African countries.

The Lancet. Global health·2021
Same author

Zoonotic Tuberculosis - The Changing Landscape.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Lethal zoonotic coronavirus infections of humans - comparative phylogenetics, epidemiology, transmission, and clinical features of coronavirus disease 2019, The Middle East respiratory syndrome and severe acute respiratory syndrome.

Current opinion in pulmonary medicine·2021

Related Experiment Video

Updated: Apr 3, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K

T-Cell Therapy: Options for Infectious Diseases.

Shreemanta K Parida1, Thomas Poiret2, Liu Zhenjiang1

  • 1Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|September 27, 2015
PubMed
Summary

Drug-resistant tuberculosis poses a global threat. T-cell therapy, leveraging immune responses, shows promise for treating drug-resistant tuberculosis when conventional treatments fail.

Keywords:
CARMtbT-cellsadoptive cell therapyhost-directed therapy

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.9K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.4K

Related Experiment Videos

Last Updated: Apr 3, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.9K
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.4K

Area of Science:

  • Immunology
  • Infectious Diseases
  • Cellular Therapy

Background:

  • Drug-resistant tuberculosis (DR-TB) presents a significant global health challenge.
  • Existing vaccines are insufficient for preventing Mycobacterium tuberculosis infection and disease.
  • Host-directed therapies are being explored as alternatives, especially for multidrug-resistant and extensively drug-resistant tuberculosis.

Purpose of the Study:

  • To review advancements in T-cell therapy.
  • To discuss the potential application of T-cell therapy in managing drug-resistant tuberculosis.
  • To explore T-cell therapy for patients with refractory tuberculosis unresponsive to standard treatments.

Main Methods:

  • Review of scientific literature on T-cell therapy.
  • Analysis of T-cell-mediated immune responses (CD8(+) and CD4(+) T cells).
  • Examination of recombinant immune recognition molecules, such as T-cell receptors and chimeric antigen receptors.

Main Results:

  • T-cell therapies have demonstrated safety and efficacy in other clinical settings, including cancer immunotherapy and viral infection prevention.
  • T-cell therapies utilize antigen-specific adaptive cellular immune responses.
  • Key achievements in T-cell therapy development have been identified.

Conclusions:

  • T-cell therapy represents a potential precision immunotherapy approach for drug-resistant tuberculosis.
  • This therapeutic strategy may offer new options for patients with limited prognoses due to refractory or drug-resistant tuberculosis.
  • Further research and clinical application of T-cell therapy are warranted for challenging tuberculosis cases.